Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Results 181 - 200 of 233 : « Previous 5 6 7 8 9 10 11 12 Next »

Recs

1
Member Avatar danmiddleton999 (< 20) Submitted: 9/21/2007 12:03:06 PM : Outperform Start Price: $22.84 BMY Score: +54.21

New stop smoking drug could be a block buster and erbitux is doing great against more types of cancer

Recs

0
Member Avatar broleen (36.61) Submitted: 9/16/2007 12:36:03 AM : Underperform Start Price: $22.35 BMY Score: -54.26

potential takeover target

Recs

1
Member Avatar LarryJThompson99 (< 20) Submitted: 8/23/2007 9:01:50 AM : Outperform Start Price: $22.98 BMY Score: +49.63

BMY had a cure for a type of cancer but bungled the drug testing. I feel they may have something that could significantly change health care. Time will tell

Recs

1
Member Avatar zimn0016 (69.20) Submitted: 8/10/2007 4:24:47 AM : Outperform Start Price: $21.72 BMY Score: +56.07

little comp. for plavix

Recs

1
Member Avatar RNZ100 (93.32) Submitted: 7/25/2007 12:55:35 AM : Outperform Start Price: $24.86 BMY Score: +41.65

Good takeover target

Recs

0
Member Avatar twocoins (72.82) Submitted: 7/23/2007 10:21:16 AM : Outperform Start Price: $25.16 BMY Score: +41.28

An old established company that pays a good dividend. Also is a speculative takeover target. Has a lot going for it in the future.

Recs

1
Member Avatar cutterrig0 (53.61) Submitted: 7/16/2007 9:51:27 PM : Outperform Start Price: $25.27 BMY Score: +41.21

good stock in good sector

Recs

1
Member Avatar gubtrito (< 20) Submitted: 7/8/2007 8:03:49 AM : Outperform Start Price: $25.01 BMY Score: +41.49

excellent product pipeline. excellent regulatory performance and Peter Dolan is not the CEO

Recs

1
Member Avatar dowup (< 20) Submitted: 6/28/2007 9:56:13 PM : Outperform Start Price: $24.95 BMY Score: +40.46

Good dividend payer & rid of recent problems. Possible takeover cantidate.

Recs

2
Member Avatar TheEndz (96.80) Submitted: 6/12/2007 11:35:09 AM : Outperform Start Price: $22.50 BMY Score: +54.25

Great Dividend 4%, Restructure in progress and possible buyout.. A must own now

Recs

0
Member Avatar bdz (83.91) Submitted: 6/8/2007 2:46:44 PM : Underperform Start Price: $22.77 BMY Score: -52.47

Troubles with some meds, but OK in long run

Recs

0
Member Avatar ThatOneGuy801 (67.89) Submitted: 5/30/2007 3:59:15 PM : Underperform Start Price: $23.51 BMY Score: -49.59

Admits to lying to the FEDs on Plavix? What to they know that investors don't? Can't be good. Thumbs down.

Recs

2
Member Avatar mcampbell8 (50.60) Submitted: 5/17/2007 10:01:25 AM : Outperform Start Price: $23.49 BMY Score: +48.54

Testing information from Chuck Allmon

Recs

2
Member Avatar donvanpatten (< 20) Submitted: 4/26/2007 7:38:09 AM : Outperform Start Price: $21.53 BMY Score: +56.92

BMY has significant troubles with pipeline and still may have a ways to go to get out of the woods from the poor management choices over the past few years. That being said the do a few things that I love:

1. Generate a lot of free cash flow
2. Have the demographics of the United States going the right direction
3. Pay a hefty dividend

While this stock will not be a home run anytime soon, it will steadily be the little train that can provide long term growth

Recs

1
Member Avatar lanhammk (80.19) Submitted: 4/13/2007 7:23:39 PM : Outperform Start Price: $22.10 BMY Score: +53.99

FDA will move this one within the month

Recs

1
Member Avatar alvesiii (74.87) Submitted: 4/10/2007 8:36:27 PM : Outperform Start Price: $21.74 BMY Score: +55.80

It will be bought out

Recs

1
Member Avatar gumbranch (< 20) Submitted: 3/24/2007 1:41:59 PM : Outperform Start Price: $21.25 BMY Score: +58.41

company is hurting from lack of new drugs but that is changing. New management solid fundamentals may take a little more time but it will be attractive in the long haul.

Recs

1
Member Avatar caplo63 (< 20) Submitted: 3/23/2007 5:56:23 PM : Outperform Start Price: $21.25 BMY Score: +58.41

Diversified; boomers reaching "that" age; mgmt learned from recent mistakes.

Recs

0
Member Avatar feorais (< 20) Submitted: 3/10/2007 7:19:00 PM : Underperform Start Price: $20.85 BMY Score: -58.88

Look at how it has underperformed over the last 7 years.

Recs

1
Member Avatar hskramer (96.02) Submitted: 2/20/2007 3:15:02 PM : Outperform Start Price: $21.24 BMY Score: +59.83

Computer generated

Featured Broker Partners


Advertisement